Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.47 |
| ▸ | FEN1 | P39748 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.41 |
| ▸ | EP300 | Q09472 | 1/20 | 0.39 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.39 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.39 |
| ▸ | MAT2A | P31153 | 2/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.38 |
| ▸ | PIM1 | P11309 | 1/20 | 0.38 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.38 |
| ▸ | CDK2 | P24941 | 1/20 | 0.38 |
| ▸ | CDK9 | P50750 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11436450 | 0.89 | PDE10A (0.51) | PDE10AFEN1SMN1; SMN2POLBGAA | |
| SCHEMBL14094434 | 0.87 | SMN1; SMN2 (0.47) | PDE10ASMN1; SMN2POLBALDH1A1GRM4 | |
| SCHEMBL8229399 | 0.80 | GRM4 (0.44) | PDE10ASMN1; SMN2POLBGAAGRM4 | |
| SCHEMBL3515107 | 0.79 | FEN1 (0.53) | PDE10AFEN1SMN1; SMN2POLBALDH1A1 | |
| SCHEMBL8419423 | 0.76 | GRM4 (0.46) | PDE10AFEN1GRM4 | |
| SCHEMBL21958529 | 0.75 | FEN1 (0.66) | FEN1SMN1; SMN2POLBALDH1A1CCNT1 | |
| SCHEMBL11434986 | 0.74 | PDE10A (0.44) | PDE10ASMN1; SMN2POLBGAAALDH1A1 | |
| SCHEMBL2068569 | 0.72 | FEN1 (0.46) | PDE10AFEN1 | |
| SCHEMBL13322658 | 0.72 | FEN1 (0.46) | FEN1SMN1; SMN2POLBALDH1A1GRM4 | |
| SCHEMBL29117987 | 0.72 | SMN1; SMN2 (0.50) | SMN1; SMN2ALDH1A1PDCD1CD274MAT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2385050-A1 | A process for preparing a substituted oxazole | Schering Corporation (US) | 2011-11-09 | — | — | EP | disclosed |
| EP-2385051-A1 | Process for making a substituted oxazole | Schering Corporation (US) | 2011-11-09 | — | — | EP | disclosed |
| EP-1758883-B1 | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors | SCHERING CORP (US) | 2011-11-02 | — | — | EP | disclosed |
| US-7985860-B2 | Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives | SCHERING CORPORATION (US) | 2011-07-26 | — | — | US | disclosed |
| US-7511062-B2 | Substituted 2-quinolyl-oxazoles useful as PDE4 inhibitors | SCHERING CORPORATION (US) | 2009-03-31 | — | — | US | disclosed |
| WO-2009009003-A1 | PROCESS FOR THE PRODUCTION OF SUBSTITUTED 5-QUINOLYL-OXAZOLES AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF | SCHERING CORPORATION (US) | 2009-01-15 | — | — | WO | disclosed |
| WO-2008021235-A2 | PROCESS AND INTERMEDIATES FOR THE SYNTHESIS OF 2-(QUINOLIN-5-YL)-4,5 DISUBSTITUTED-AZOLE DERIVATIVES | SCHERING CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
| US-20080045718-A1 | Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives | MERCK SHARP & DOHME CORP. | 2008-02-21 | — | — | US | disclosed |
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
| US-7220735-B2 | Benzimidazolone histamine H3 antagonists | SCHERING CORPORATION (US) | 2007-05-22 | — | — | US | disclosed |
| WO-2005116009-A1 | SUBSTITUTED 2-QUINOLYL-OXAZOLES USEFUL AS PDE4 INHIBITORS | SCHERING CORPORATION (US) | 2005-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142369-A1 | Combination of an H3 antagonist/inverse agonist and an appetite suppressant | CNR2, GPR119, GLP1R | PDE10A 1789/4885FEN1 4450/4885SMN1; SMN2 4298/4885 |
| US-20080045718-A1 | Process and intermediates for the synthesis of 2-(quinolin-5-yl)-4,5 disubstituted-azole derivatives | PDE4B, PDE4A, PDE3B | PDE10A 19/4885FEN1 3039/4885SMN1; SMN2 4433/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.